Frontiers An overview of agents and treatments for PDGFRA

lt;p>Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–15% of gastrointestinal stromal tumors (GISTs). These tumors with P

Treatment of advanced gastrointestinal stromal tumors (GIST) PDGFRA

Frontiers Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

PDGFR signal transduction and links to the cytoskeleton. (A) The

Molecular targeted therapy: A new avenue in glioblastoma treatment (Review)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor - John R. Zalcberg, 2021

KIT and PDGFRA downstream signaling pathways. Abbreviations: SCF, stem

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward - M. Julia Lostes-Bardaji, David García-Illescas, Claudia Valverde, César Serrano, 2021

Frontiers Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib

New insights about the PDGF/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies - ScienceDirect

Location and frequency of primary mutations in KIT and PDGFRA.

Frontiers Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor

Frontiers Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment

New insights about the PDGF/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies - ScienceDirect

Cancers, Free Full-Text